Phases, active trials: Phase 1: 2, Phase 1/2: 4, Phase 2: 19, Phase 2/3: 3, Phase 3: 41, Phase 4: 7, No phase listed: 46
Takeda's pipeline spans oncology, gastroenterology, rare disease, and plasma-derived therapies. Their oncology franchise includes Alunbrig (brigatinib) for ALK-positive NSCLC, competitive with Lorbrena in the post-crizotinib setting, and Ninlaro (ixazomib), the first oral proteasome inhibitor for multiple myeloma. In gastroenterology, Entyvio (vedolizumab) for IBD has one of the most active label expansion programs in the specialty. Their rare disease portfolio (alpha-1 antitrypsin deficiency, Fabry disease, hereditary angioedema) continues generating Phase 3 trials. Takeda is also advancing TAK-279 (zasocitinib), a TYK2 inhibitor, as a potential competitor to Bristol Myers Squibb's deucravacitinib in psoriasis and PsA.
- Oncology (NSCLC, multiple myeloma, lymphoma)
- Gastroenterology / IBD
- Rare / plasma-derived
- Neuroscience
- Immunology (TYK2, IL)
- Alunbrig (brigatinib): ALK inhibitor, NSCLC
- Ninlaro (ixazomib): oral proteasome inhibitor, myeloma
- Entyvio (vedolizumab): α4β7 integrin, IBD/Crohn's/UC
- TAK-279 (zasocitinib): TYK2 inhibitor, psoriasis/PsA
- Fruquintinib: VEGFR 1/2/3 inhibitor, CRC (via Zymeworks)
- TAK-981: SUMO pathway inhibitor, lymphoma
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Gaucher Disease Outcome Survey (GOS) NCT03291223 | Primary completion moved 2 years later | Recruiting |
11 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of TAK-360 in Adults With Idiopathic Hypersomnia NCT06812078 | Nov 30, 2026 · Estimated | Phase 2 |
9 more on the Completions page. See the calendar →
Monitor the Takeda pipeline daily
Get a daily digest when Takeda registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Crohn's Disease | 13 |
| Ulcerative Colitis | 9 |
| Dengue Fever | 5 |
| Narcolepsy Type 1 | 5 |
| Alpha1-Antitrypsin Deficiency | 4 |
| Colorectal Cancer | 4 |
| Cytomegalovirus (CMV) | 4 |
| Hereditary Angioedema (HAE) | 4 |
Takeda's TYK2 inhibitor zasocitinib is the most significant competitive threat to BMS's deucravacitinib (Sotyktu) in the psoriasis/PsA space. Any dermatology-focused company should monitor Takeda's Phase 3 program. In GI, new Entyvio combinations and IBD programs are closely watched by companies developing competing gut-selective biologics.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Takeda's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Takeda may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Takeda pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if… NCT05899673 | Active, Not Recruiting | Enrollment increased: 31 → 200 participants | 2026-11-13 |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058 | Recruiting | Trial sites expanded: 78 → 111 locations | 2026-11-13 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken… NCT06671483 | Active, Not Recruiting | Trial sites reduced: 188 → 184 locations | 2026-11-13 |
| A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea NCT06550882 | Recruiting | Study completion pushed from Dec 31, 2026 to Dec 31, 2028 | 2026-11-10 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With… NCT07422480 | Recruiting | Trial sites expanded: 162 → 166 locations | 2026-11-07 |
Each trial page shows every change DataLookout has recorded for that trial.